LeonaBio, Inc. 8-K/A

What Happened

• LeonaBio, Inc. filed an amendment to its earlier 8‑K to report a material licensing and related securities transaction with Sermonix (the "Sermonix License" and associated securities purchase and registration/right agreements). The amendment adds the full Sermonix License and related agreement forms as exhibits and updates prior references from Athira Pharma to LeonaBio.
• The filing discloses cash spending on the ELAINE‑3 clinical study: Sermonix reported approximately $14 million (2023), $12 million (2024), and $5 million (through Dec 18, 2025). LeonaBio reports it made about $11 million in cash expenditures for ELAINE‑3 from Dec 18–31, 2025, and expects to spend approximately $45 million in 2026 and $30 million in 2027 to conduct the study.
• The company amended the ELAINE‑3 protocol to increase sample size from 500 to up to 600 participants, expects to complete enrollment in Q4 2026, and to release topline data in the second half of 2027. LeonaBio also says it has entered new CRO and CMO agreements that expand scope and costs versus the contracts Sermonix had in place.

Key Details

• Sermonix reported cash outlays for ELAINE‑3: ~$14M (2023), ~$12M (2024), ~$5M (through Dec 18, 2025).
• LeonaBio cash expenditures for ELAINE‑3: ~ $11M (Dec 18–31, 2025); projected spend ≈ $45M (2026) and ≈ $30M (2027).
• ELAINE‑3 study amended to up to 600 participants (from 500); enrollment completion targeted in Q4 2026; topline data expected H2 2027.
• Full Sermonix License and related securities agreements (Sermonix Securities Purchase Agreement, Registration Rights Agreement, Pre‑Funded Warrant form) are attached as exhibits to the filing.

Why It Matters

• The filing provides concrete past and projected cash needs for the ELAINE‑3 trial, signaling materially higher R&D spend in 2026–2027 versus amounts previously incurred by Sermonix. That affects LeonaBio’s near‑term cash requirements and planning.
• Increasing the trial size to up to 600 participants and expanded CRO/CMO scope indicate a ramped‑up development program and set expectations for timing of enrollment completion and topline results (Q4 2026 and H2 2027, respectively).
• Investors should note the company added the full license and securities agreements to the record and updated the registrant name to LeonaBio; these exhibits contain the definitive legal terms governing the transaction.